Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study

Basic Details
Tuesday, November 14, 2017
Medical Product
Health Outcome(s)
atrial fibrillation
extracranial bleeding
intracranial hemorrhage
ischemic stroke
myocardial infarction

Dabigatran (150 mg twice daily) has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clinical practice are limited. The authors of this article compared incidence of stroke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practice. The authors found that in matched adults with atrial fibrillation treated in practice, the incidences of stroke and bleeding with dabigatran versus warfarin were consistent with those seen in trials. The possible relationship between dabigatran and myocardial infarction warrants further investigation.

Time Period
2010 - 2014
Population / Cohort
All individuals 18 years of age or older

Alan S. Go MD; Daniel E. Singer MD; Sengwee Toh ScD; T. Craig Cheetham PharmD, MS; Marsha E. Reichman PhD; David J. Graham MD, MPH; Mary Ross Southworth PharmD; Rongmei Zhang PhD; Rima Izem PhD; Margie R. Goulding PhD; Monika Houstoun PharmD; Katrina Mott MS; Sue Hee Sung MPH; Joshua J. Gagne PharmD, ScD